Zobrazeno 1 - 10
of 95
pro vyhledávání: '"W W, ten Bokkel Huinink"'
Autor:
Rolf A. Stahel, Karin Mattson, N. v. Walree, K. Liippo, Joachim von Pawel, Peter Drings, P. Kellokumpu-Lehtinen, Christian Manegold, W. W. ten Bokkel-Huinink, C. Sederholm, S. Ricci, Gunnar Wagenius, B. Bergman, W. Dornoff, Assad Chemaissani
Publikováno v:
Annals of Oncology. 8:525-529
Summary Background This randomised study was designed to determine the response rate, survival and toxicity of single-agent gemcitabine and cisplatin-etoposide in chemo-naive patients with locally advanced or metastatic non-small-cell lung cancer. Pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ab5b5e1549977eb294f5e38923e8316
https://doi.org/10.1023/a:1008207731111
https://doi.org/10.1023/a:1008207731111
Autor:
W. W. ten Bokkel-Huinink, Auke Bult, B. G. Taal, Hilde Rosing, O. van Tellingen, A. C. Dubbelman, J. D. Jonkman-de Vries, Jos H. Beijnen, C. Neef
Publikováno v:
Clinical Drug Investigation. 10:86-95
The effects of the primary tumour in situ or of gastrectomy on the bioavailability and other pharmacokinetic parameters of etoposide, after oral administration of commercially available etoposide (Vepesid®, Bristol-Myers Squibb) capsules, were studi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0aa14831aaeba86d5ea80657abfeca9c
https://doi.org/10.2165/00044011-199510020-00003
https://doi.org/10.2165/00044011-199510020-00003
Publikováno v:
The Netherlands Journal of Medicine. 46:62-72
Objective: (1) To assess plasma renin activity (PRA) and plasma aldosterone concentration (PAC) in patients with inferior vena cava syndrome (IVCS). (2) To study in an open fashion the efficacy of loop diuretic treatment, single, or in combination wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::194bd42f0975057f4f11c72c5f7672f7
https://doi.org/10.1016/0300-2977(94)00096-r
https://doi.org/10.1016/0300-2977(94)00096-r
Autor:
P. A. v. d. Wouw, H. H. v. Rooy, R. W. Koster, A. J. Porsius, R. G. A. van Wayjen, A. van den Ende, R. G. L. van Tol, T. R. MacGregor, J. Mooy, B. c. Arends, R. Böhm, J. v. Kemenade, M. v. Baak, K. H. Rahn, P. P. Koopmans, Th. Thien, C. M. C. Thomas, F. W. J. Gribnau, J. G. Timmer, A. Vyth, W. Th. Kok, J. M. B. V. de Jong, W. A. den Hartog Jager, J. W. P. M. Overdiek, F. H. H. M. Merkus, M. A. van Bàak, D. de Ryckc, O. Teirlynck, M. G. Bogaert, P. Smits, A. van 't Laar, B. A. M. van Schaik, G. G. Geyskes, J. C. Roos, E. J. Dorhout Mees, G. J. Navis, P. E. de Jong, A. J. M. Donker, G. K. v. d. Hem, D. de Zeeuw, A. H. van den Meiracker, A. J. Man in't Veld, C. J. R. Ritsema, null van Eck, F. H. M. Derkx, M. A. D. H. Schalekamp, J. H. M. Berkelmans, H. Wollersheim, A. C. Dullemond-Westland, J. P. Neijt, J. W. R. Nortier, J. M. A. Sitsen, P. Vermeij, P. M. Edelbroek, M. D. Ferrari, O. J. S. Buruma, F. A. de Wolff, F. Elferink, W. J. F. van der Vijgh, I. Klein, W. W. ten Bokkel Huinink, H. M. Pinedo, M. Raghoebar, H. L. G. M. Tiemessen, P. L. C. M. van Kiel, W. B. van den Berg, C. A. M. van Ginneken
Publikováno v:
Pharmacy World & Science. 15:3A-9A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1459bb30df94a7ab5ac0d3e711b8d3b3
https://doi.org/10.1007/bf01884918
https://doi.org/10.1007/bf01884918
Autor:
W W, ten Bokkel Huinink, C J, van Groeningen, E E, Voest, W G, Peters, H J, Keizer, J H, de Witte
Publikováno v:
The Netherlands journal of medicine. 61(7)
Irinotecan is an effective treatment for metastatic colorectal cancer. However, its use may be associated with troublesome adverse effects such as delayed diarrhoea, acute cholinergic syndrome and neutropenic infection. The manufacturer decided to re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e536842121b51fc660ec9444b47502b2
https://pubmed.ncbi.nlm.nih.gov/14567522
https://pubmed.ncbi.nlm.nih.gov/14567522
Autor:
J M, Meerum Terwogt, M M, Malingré, J H, Beijnen, W W, ten Bokkel Huinink, H, Rosing, F J, Koopman, O, van Tellingen, M, Swart, J H, Schellens
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5(11)
i.v. paclitaxel is inconvenient and associated with significant and poorly predictable side effects largely due to the pharmaceutical vehicle Cremophor EL. Oral administration may be attractive because it may circumvent the use of Cremophor EL. Howev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b9891d35e4bd0bb594a0ae0108b86cf7
https://pubmed.ncbi.nlm.nih.gov/10589748
https://pubmed.ncbi.nlm.nih.gov/10589748
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 10
Oxaliplatin [trans-1-diaminocyclohexane (DACH) platinum, L-OHP] was brought into clinical evaluation in ovarian cancer because of the in vitro and in vivo antitumour activity observed in experimental models resistant to cisplatin. The antitumour acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6581e1c93fb8663bb2490dfbd592c2d3
https://pubmed.ncbi.nlm.nih.gov/10219454
https://pubmed.ncbi.nlm.nih.gov/10219454
Publikováno v:
Pharmacy worldscience : PWS. 20(4)
In this review the clinical pharmacokinetics of camptothecin topoisomerase I inhibitors, an important new class of anticancer drugs, is discussed. Two prototypes, topotecan and irinotecan, are currently marketed in many European countries and the USA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::42ed0a684d48cc3e8d1cf9fc5352c277
https://pubmed.ncbi.nlm.nih.gov/9762728
https://pubmed.ncbi.nlm.nih.gov/9762728
Publikováno v:
European journal of nuclear medicine. 25(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ce5dde8a2f3884c32ea0634f1e10c677
https://pubmed.ncbi.nlm.nih.gov/9643974
https://pubmed.ncbi.nlm.nih.gov/9643974
Autor:
V R, Panday, M T, Huizing, P H, Willemse, A, De Graeff, W W, ten Bokkel Huinink, J B, Vermorken, J H, Beijnen
Publikováno v:
Seminars in oncology. 24(4 Suppl 11)
Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has been demonstrated to be an active anticancer agent, including in platinum-refractory ovarian cancer. The pharmacokinetics of paclitaxel have been extensively described. It displays n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::92baf1373727af7ee45792acd7a86bad
https://pubmed.ncbi.nlm.nih.gov/9314297
https://pubmed.ncbi.nlm.nih.gov/9314297